Alkem Labs Receives GST Demand Orders Totaling ₹1.89 Crore
Alkem Laboratories received two GST demand orders totaling ₹1.89 crore, including penalties and interest. The orders, received on December 26, 2025, allege excess ITC availment. The company disputes the demands and plans to appeal, stating no material financial impact.
The company explicitly stated that there is no material impact on its financial, operational, or other activities, and the total demand is a relatively small amount compared to the company's overall scale.
The company received GST demand orders, which are typically negative. However, the company disputes the demands, plans to appeal, and states there is no material financial impact, leading to a neutral sentiment.
Alkem Laboratories Limited has announced the receipt of two orders from statutory authorities under the Goods and Services Tax (GST) Act, 2017. The first order, from the Assistant Commissioner, Central Goods and Services Tax, Ambala, Haryana, pertains to the financial year 2021-22. It demands GST of ₹1,83,14,281 along with a penalty of ₹18,31,428 and applicable interest. The order alleges excess availment of Input Tax Credit (ITC), a claim the company disputes.
The second order, from the Superintendent, CGST Range-XXXV, CGST Division- G, Jaipur, relates to the financial year 2018-19. This order demands GST of ₹6,12,474, a penalty of ₹6,12,474, and applicable interest. The company also disputes this demand, citing alleged excess availment of ITC.
Both orders were received by the company on December 26th, 2025. Alkem Laboratories stated that it does not agree with the demands and intends to contest them, including by filing appeals. The company has indicated that these orders will not have a material impact on its financial, operational, or other activities. The announcement was made on December 29th, 2025, the first working day after the receipt of the orders.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.